Click on any title below to learn more about it.
|
Title |
Author |
Status |
Type |
|
|
A treater's perspective |
Kimberly Smith; Richard Cazen; Danielle Milano; Charles Steinberg |
|
|
Login |
|
Description
This program was developed by Serono Symposia International, Inc.
This educational program was designed to provide physicians, nurses, and pharmacists with the most up-to-date information
on wasting in HIV disease.
Learning objectives
- Review the incidence of HIV-associated wasting in the era of HAART
- Identify the most accurate methods for diagnosis of wasting
- Distinguish HIV wasting from lipoatrophy
- Define HIV-associated wasting
- Analyze currently available therapies and develop optimal treatment recommendations
|
|
Body composition and bioelectrical impedance analysis |
Cade Fields-Gardner |
|
|
Login |
|
Description
This program was developed by Serono Symposia International, Inc.
The goal of this program is to provide physicians, nurses, pharmacists, registered dietitians and other allied health professionals
with practical information that will allow you to start using or better understand your use of BIA technology in medical practice.
Learning objectives
- List four methods of body composition evaluation that may be used in conjunction with BIA evaluation
- Describe three body “compartments”
- Explain reasons for increases and decreases in body compartments
- Interpret standard 3-compartment BIA report
|
|
Clinical perspectives on HIV |
Julian Falutz; Donald Kotler; Abby Shevitz; Christine Wanke |
|
|
Login |
|
Description
The goal of this educational activity was to provide a clearer understanding of HIV-associated lipodystrophy syndrome, an
umbrella term used to describe various metabolic and morphologic changes that sometimes accompany HIV infection, particularly
in patients taking antiretroviral agents. Although estimates of patients with genetic or non-HIV-related acquired lipodystrophy
in the medical literature number only a few hundred, a few thousand cases were reported at the First International Workshop
on Adverse Drug Reactions and Lipodystrophy in HIV in San Diego, June 26-28, 1999. The prevalence of the HIV-associated syndrome
remains unclear, partly because a working definition for the condition has been difficult to develop.
This educational program was designed to provide physicians, nurses and pharmacists with current information on HIV-associated
lipodystrophy syndrome and to clarify issues surrounding its diagnosis and management.
Learning objectives
Upon completion of this program, the participant will be able to:
- Evaluate current opinion and data on the prevalence and manifestations of HIV-associated lipodystrophy syndrome
- Describe etiologic factors thought to contribute to changes in metabolism and body shape in patients who have the syndrome
- Explain current approaches to diagnosing and assessing manifestations of HIV-associated lipodystrophy syndrome
- Describe the potential sociologic and long-term health consequences of HIV-associated lipodystrophy syndrome
- Evaluate and prescribe pharmacologic treatments and nonpharmacologic interventions based on the best available evidence
|
|
GH replacement in adult GH deficiency |
Rolf-Christian Gaillard |
|
|
Login |
|
Description
This online CME program – presented during the 6th European Congress of Endocrinology (EFES) in Lyons, France on April 26,
2003, at the Serono Symposia International Satelitte Symposium – reviewed the results of a clinical study that evaluated the
effects and safety of r-hGH replacement therapy in Adult Growth Hormone Deficiency (AGHD). The results of a short-term double-blind
placebo controlled phase of 6 months were provided together with a long-term open-label phase up to 30 months and confirmed
the sustained benefits and safety of r-hGH replacement therapy in AGHD.
Learning objectives
Upon completion of this program, the participant will be able to:
- Identify the results of a clinical study that evaluates the effects of r-hGH replacement therapy in AGHD
- Understand the short and long-term clinical benefits of r-hGH replacement therapy on body composition and cardiac function
in AGHD
- Discuss the safety aspects of r-hGH replacement therapy in AGHD
|
|
Guidelines for using body composition measurements |
Bruce Polsky; Donald Kotler; Christine Wanke |
|
|
Login |
|
Description
This program was developed by Serono Symposia International, Inc.
The following guidelines were specifically designed to help clinicians use BIA to diagnose HIV-associated wasting, and also
to monitor body composition in patients who have been placed on wasting therapies. The faculty hoped these guidelines would
assist providers as they make important clinical decisions affecting patient care.
Learning objectives
- Identify the clinical signs of HIV-associated wasting and fat redistribution syndrome, and differentiate the two conditions
- Select the optimal way to measure changes in body composition associated with HIV-associated wasting and fat redistribution
syndrome
- Evaluate the effect on HIV-associated wasting and fat redistribution syndrome using body composition measurements
|
|
Is aging a disease? |
George Merriam; Felice Strollo; Richard Walker |
|
|
Login |
|
Description
Serono Symposia International Foundation would like to thank Dr Merriam, Professor Strollo, and Dr Walker for their presentations
at the sponsored Symposia at the 3rd World Congress on The Aging Male. Each of these presentations provided insight and background
into the biologic processes that contribute to aging, and the ways in which growth hormone (GH), and other factors associated
with the hypothalamo-pituitary axis may prevent or reverse some of these processes.
The target audience was physicians and other health professionals interested or trained in Endocrinology.
Learning objectives
Upon completion of this program, the participant will be able to:
- Differentiate the process of aging from the conditions of disease
- Identify the pathophysiological mechanisms involved in the overall decline of pineal, pituitary, thyroid, parathyroid, gonadal
and medullary adrenal function in the elderly
- Evaluate age-related changes in homeostasis regulating systems in different neuroendocrine axis
- Identify different treatments approaches in aging
|
|
Morbidity of adults as small for gestational age |
Klaus L. Mohnike; Paul Saenger |
|
|
Login |
|
Description
The morbidity of children and adults born small for gestational age (SGA) is still poorly understood and it is unclear if
SGA will lead to Syndrome X in childhood. Around 100,000 children are born with SGA annually in the U.S. alone, the public
health aspects of SGA are of great importance.
The target audience was physicians and other health professionals interested or trained in Endocrinology, Pediatrics and growth
related disorders.
Learning objectives
Upon completion of this program, the participant will be able to:
- Understand the relationship of INS VNTR (insulin; variable numbers of tandem repeats)
- Examine the influence of foetal growth restraint and postnatal growth rate on the risk of Type 2 diabetes and the effect of
INS VNTR genotype
- Describe the mechanisms of underlying hypothalamic ‘malprogramming’
- Outline the role of foetal and neonatal nutrition in strategies for the prevention of Syndrome X
- Identify the long-term consequences in patients diagnosed with idiopathic premature pubarche
- Describe the clinical and hormonal characteristics of those girls with premature adrenarche who may be at risk of the insulin
resistance syndrome/polycyctic ovary syndrome (PCOS)
- Understand the significant relationship between metabolic disorders and familial risk in SGA patients
- Understand the cellular mechanisms and the clinical implications of insulin resistance
- Define the susceptibility to develop insulin resistance, which seems to be restricted to a subpopulation of SGA adults born
- Assess the risk for developing the metabolic syndrome (or its components) in the offspring of affected patients
|
|
Morphologic and metabolic complications of HIV and HAART |
Eric Daar; Kimberly Smith; David Rubin; Corklin Steinhart |
|
|
Login |
|
Description
This program was developed by Serono Symposia International, Inc.
This educational program was designed to provide physicians, nurses, and pharmacists with the most up-to-date information
on the morphologic and metabolic complications of HIV and HAART.
Learning objectives
Upon completion of this program, the participant will be able to:
- Identify common morphlogic complications of HIV disease and HAART
- Discuss emerging treatment options for HIV-associated fat redistribution syndrome
- Review current data on metabolic complications of HIV disease and HAART
- Discuss the prevalence, gender differences, impact on therapy, adherence, and quality-of-life issues of these complications
- Develop clinical management strategies
|
|
Severe systemic complications of acromegaly |
Annamaria Colao |
|
|
Login |
|
Description
This online CME program is based on a presentation made at the Serono Symposia International Foundation event International
Symposium on Growth Hormone which took place in Santiago de Compostela, November 18-20, 2004.
Acromegaly is a rare disease characterized by progressive somatic disfigurement and a wide range of systemic manifestations.
At diagnosis, patients generally exhibit coarsened facial features, exaggerated growth of hands and feet, and soft tissue
hypertrophy. Other characteristics may include cardiovascular disease, respiratory disorders and various other osteo-skeletal
complications. Early diagnosis and intervention may help prevent these complications and help normalize life expectancy in
patients with the disease.
The goal of this program is to provide endocrinologists, pediatric endocrinologists and other healthcare providers with an
understanding of the severe systemic complications of acromegaly.
Learning objectives
Upon completion of this program, the participant will be able to:
- Discuss the most common causes of mortality in patients with acromegaly
- Describe the complications of acromegaly associated with the cardiovascular, respiratory and osteo-skeletal systems
- Apply therapeutic strategies for the treatment and management of these complications
- Discuss the oncological risk in patients with acromegaly
|